Cerecor Inc (NASDAQ:CERC): Steven Boyd’s Armistice Capital filed an amended 13D.
You can check out Armistice Capital’s latest holdings and filings here.
Please follow Armistice Capital (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Armistice Capital or update its stock holdings.
Follow Steven Boyd's Armistice Capital
You can access the original SEC filing by clicking here.
Ownership Summary Table
Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
---|---|---|---|---|---|---|
Armistice Capital | 0 | 30,155,584 | 0 | 30,155,584 | 30,155,584 | 74.8% |
Armistice Capital Master Fund, Ltd | 0 | 30,155,584 | 0 | 30,155,584 | 30,155,584 | 74.8% |
Steven Boyd | 0 | 30,155,584 | 0 | 30,155,584 | 30,155,584 | 74.8% |
Follow Steven Boyd's Armistice Capital
Page 1 of 11 – SEC Filing
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
SCHEDULE
13D
THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No.3)*
Cerecor Inc. |
(Name of Issuer) |
Common Stock, $0.001 par value |
(Title of Class of Securities) |
15671L109 |
(CUSIP Number) |
Tohuan Steve Chen c/o Armistice Capital LLC 510 Madison Avenue 22nd Floor New York, NY 10022 Telephone Number: 212-231-4930 |
(Name, Address and Telephone Number of Person Notices and Communications) |
August 25, 2017 |
(Date of Event Which Requires Filing of this Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [_]. | |
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. |
Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)
Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)
Page 2 of 11 – SEC Filing
CUSIP No. | 15671L109 |
1. | NAME OF REPORTING PERSONS | |
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) | ||
Armistice Capital, LLC |
2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) | [_] |
(b) | [_] |
3. | SEC USE ONLY | |
4. | SOURCE OF FUNDS | |
AF |
5. | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) | [_] |
6. | CITIZENSHIP OR PLACE OF ORGANIZATION | |
Delaware |
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON |
7. | SOLE VOTING POWER | |
0 |
8. | SHARED VOTING POWER | |
30,155,584 |
9. | SOLE DISPOSITIVE POWER | |
0 |
10. | SHARED DISPOSITIVE POWER | |
30,155,584 |
11. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | |
30,155,584 |
12. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | [_] |
13. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) | |
74.8% |
14. | TYPE OF REPORTING PERSON | |
IA, OO |
Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)
Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)
Page 3 of 11 – SEC Filing
CUSIP No. | 15671L109 |
1. | NAME OF REPORTING PERSONS | |
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) | ||
Armistice Capital Master Fund, Ltd. |
2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) | [_] |
(b) | [_] |
3. | SEC USE ONLY | |
4. | SOURCE OF FUNDS | |
WC |
5. | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) | [_] |
6. | CITIZENSHIP OR PLACE OF ORGANIZATION | |
Cayman Islands |
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON |
7. | SOLE VOTING POWER | |
0 |
8. | SHARED VOTING POWER | |
30,155,584 |
9. | SOLE DISPOSITIVE POWER | |
0 |
10. | SHARED DISPOSITIVE POWER | |
30,155,584 |
11. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | |
30,155,584 |
12. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | [_] |
13. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) | |
74.8% |
14. | TYPE OF REPORTING PERSON | |
CO |
Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)
Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)
Page 4 of 11 – SEC Filing
CUSIP No. | 15671L109 |
1. | NAME OF REPORTING PERSONS | |
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) | ||
Steven Boyd |
2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) | [_] |
(b) | [_] |
3. | SEC USE ONLY | |
4. | SOURCE OF FUNDS | |
AF |
5. | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) | [_] |
6. | CITIZENSHIP OR PLACE OF ORGANIZATION | |
United States of America |
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON |
7. | SOLE VOTING POWER | |
0 |
8. | SHARED VOTING POWER | |
30,155,584 |
9. | SOLE DISPOSITIVE POWER | |
0 |
10. | SHARED DISPOSITIVE POWER | |
30,155,584 |
11. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | |
30,155,584 |
12. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | [_] |
13. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) | |
74.8% |
14. | TYPE OF REPORTING PERSON | |
IN, HC |
Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)
Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)
Page 5 of 11 – SEC Filing
CUSIP No. | 15671L109 |
Item 1. | Security and Issuer. |
The name of the issuer is Cerecor Inc., a Delaware corporation (the “Issuer”). The address of the Issuer’s principal executive offices is 400 E. Pratt Street, Suite 606, Baltimore, Maryland 21202. This Amendment No. 3 to Schedule 13D relates to the Issuer’s Common Stock, $0.001 par value (the “Shares”). | ||
Item 2. | Identity and Background. |
(a), (f) | The persons filing this statement are Armistice Capital, LLC, a Delaware limited liability company (“Armistice Capital”), Armistice Capital Master Fund, Ltd., a Cayman Islands corporation (the “Master Fund”), and Steven Boyd, a United States citizen (“Mr. Boyd”, and collectively with Armistice Capital and the Master Fund, the “Reporting Persons”). | ||
(b), (c) | Armistice Capital is an investment adviser The Master Fund is principally engaged in the Steven Boyd is the managing member of Armistice | ||
(d) | None of the Reporting Persons have, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). | ||
(e) | None of the Reporting Persons have, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. |
Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)
Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)
Page 6 of 11 – SEC Filing
Item 3. | Source and Amount of Funds or Other Consideration. | |
The funds for the purchase of the 30,155,584 Shares beneficially owned by the Reporting Persons came from working capital of the Master Fund, which is the direct owner of the Shares. The net investment costs (including commissions, if any) of the Shares beneficially owned by the Reporting Persons is approximately $5,900,070. No borrowed funds were used to purchase the Shares, other than any borrowed funds used for working capital purposes (including certain leverage arrangements) in the ordinary course of business. | ||
Item 4. | Purpose of Transaction. | |
The Reporting Persons are filing this Schedule On April 27, 2017, the Issuer and the Master In addition, pursuant to the terms of the Issuer’s |
Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)
Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)
Page 7 of 11 – SEC Filing
In connection with the private placement, the On April 28, 2017, the Issuer issued a press The foregoing was a summary of the Press The Reporting Persons intend to review Except as otherwise set forth herein, the Reporting |
Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)
Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)
Page 8 of 11 – SEC Filing
Item 5. | Interest in Securities of the Issuer. | ||
(a) – (d) | As of the date hereof, each of the Reporting The transactions in the Shares by the Reporting | ||
(e) | N/A |
Item 6. | Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer. | |
The information set forth in Item 4 above is |
Item 7. | Material to be Filed as Exhibits. |
Exhibit A: | Joint Filing Agreement | |
Exhibit B: | Schedule of Transactions in the Shares | |
Exhibit C: | Press Release of Cerecor Inc., dated April 28, 2017 (incorporated by reference to Exhibit 99.1 to the Form 8-K filed with the SEC by the Issuer on April 28, 2017) | |
Exhibit D: | Securities Purchase Agreement, dated April 27, 2017 (incorporated by reference to Exhibit 10.1 to the Form 8-K filed with the SEC by the Issuer on April 28, 2017) | |
Exhibit E: | Form of Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock of Cerecor Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed with the SEC by the Issuer on April 28, 2017) | |
Exhibit F: | Registration Rights Agreement, dated April 27, 2017 (incorporated by reference to Exhibit 10.2 to the Form 8-K filed with the SEC by the Issuer on April 28, 2017) |
Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)
Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)
Page 9 of 11 – SEC Filing
SIGNATURE
After reasonable inquiry
and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
August 30, 2017 | ||
(Date) | ||
Armistice Capital, LLC* | ||
By: /s/ Steven Boyd | ||
Name: Steven Boyd Title: Managing Member | ||
Armistice Capital Master Fund, Ltd. | ||
By: /s/ Steven Boyd | ||
Name: Steven Boyd Title: Director | ||
Steven Boyd* | ||
/s/ Steven Boyd |
* The Reporting Person disclaims beneficial
ownership of the reported securities except to the extent of its pecuniary interests therein, and this report shall not be deemed
an admission that such person is the beneficial owner of these securities for purposes of Section 16 of the U.S. Securities Exchange
Act of 1934, as amended, or for any other purpose.
Attention: Intentional misstatements or omissions of fact constitute
Federal criminal violations (see 18 U.S.C. 1001).
Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)
Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)
Page 10 of 11 – SEC Filing
Exhibit A
AGREEMENT
The undersigned agree that
this Amendment No. 3 to Schedule 13D, dated August 30, 2017, relating to the Common Stock, $0.001 par value, of Cerecor Inc. shall
be filed on behalf of the undersigned.
August 30, 2017 | ||
(Date) | ||
Armistice Capital, LLC | ||
By: /s/ Steven Boyd | ||
Name: Steven Boyd Title: Managing Member | ||
Armistice Capital Master Fund, Ltd. | ||
By: /s/ Steven Boyd | ||
Name: Steven Boyd Title: Director | ||
Steven Boyd | ||
/s/ Steven Boyd |
Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)
Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)
Page 11 of 11 – SEC Filing
Exhibit B
Schedule of Transactions in the
Shares
Trade Date | Purchase/Sale | Quantity | Price |
7/06/2017 | Purchase* | 11,940,000 | $0.35* |
8/14/2017 | Purchase | 175,776 | $0.64 |
8/15/2017 | Purchase | 65,500 | $0.58 |
8/16/2017 | Purchase | 76,800 | $0.58 |
8/17/2017 | Purchase | 26,002 | $0.5863 |
8/18/2017 | Purchase | 31,698 | $0.6091 |
8/21/2017 | Purchase | 15,564 | $0.6126 |
8/22/2017 | Purchase | 19,301 | $0.6163 |
8/23/2017 | Purchase | 900 | $0.6186 |
8/24/2017 | Purchase | 19,944 | $0.6991 |
8/25/2017 | Purchase | 38,328 | $0.7538 |
8/28/2017 | Purchase | 25,321 | $0.7257 |
8/29/2017 | Purchase | 50,000 | $0.7159 |
8/30/2017 | Purchase | 512 | $0.736 |
* The Reporting Persons converted their 4,179
shares of the Issuer’s Series A Convertible Preferred Stock into 11,940,000 Shares at the conversion price of $0.35 per share.